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Introduction
Chemokines are chemoattractant and immunomodula-
tory molecules that play a central role in many inflam-
matory processes (1). Chemokines are divided into four
structural groups based on the number and arrangement
of conserved cysteines and are consequently named CC,
CXC, C, and CX3C chemokines. CC chemokines general-
ly regulate macrophages and lymphocytes, while CXC
chemokines stimulate the activity of neutrophils as well
as regulate lymphocyte activity and development. The
only members of the C and CX3C chemokine families are
lymphotactin and fractalkine, respectively, and their
physiologic roles are not completely understood.
Given the importance of chemokines in the immune
system, it is not surprising that viruses have evolved
mechanisms for interacting with the chemokine sys-
tem. Poxviruses and herpesviruses use multiple strate-
gies for interacting with the chemokine system, includ-
ing virus-encoded chemokine receptor homologues
and virus-encoded chemokine homologues (2–6). An
additional strategy, secretion of chemokine-binding
proteins, was originally described in poxviruses (5, 6)
and has subsequently been demonstrated for the γ-her-
pesvirus, γHV68 (7, 8).
Two distinct types of DNA viruses, poxviruses and
herpesviruses, express high-affinity chemokine-bind-
ing proteins (CBPs). Poxvirus CBPs are involved in reg-
ulating inflammation during acute infection. Myxoma
viruses deficient in production of the CBP T7 have dra-
matic reduction in disease symptoms and viral dissem-
ination to secondary sites, as well as a marked increase
of leukocyte infiltration into the site of infection (9).
Myxoma viruses deficient in CBP T1 have a more sub-
tle phenotype, with an increase in leukocyte infiltra-
tion, but no significant difference in disease progres-
sion or mortality (10, 11).
Limitation of inflammatory chemokine action dur-
ing acute infection may be similarly important for the
pathogenesis of disease caused by herpesviruses. How-
ever, γ-herpesviruses have a unique relationship with
hematopoietic cells that is not shared with poxviruses.
Unlike poxviruses, γ-herpesviruses require hematopoi-
etic cells for latency and long-term persistence in the
host and are capable of causing chronic diseases includ-
ing lymphomas and arteritis of the great vessels (12,
13). It is therefore possible that chemokines and CBPs
play a role in acute γ-herpesvirus infection (similar to
poxviruses) and or chronic γ-herpesvirus infection.
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Chemokines are involved in recruitment and activation of hematopoietic cells in sites of infection and
inflammation. The M3 gene of the γ-herpesvirus γHV68 encodes an abundant secreted protein that
binds CC chemokines with high affinity. We report here that this gene is essential for efficient induc-
tion of lethal meningitis by γHV68. An M3 mutant γHV68 (γHV68-M3.stop) was 100-fold less virulent
than wild-type or marker rescue control (γHV68-M3.MR) viruses after intracerebral inoculation. After
intracerebral inoculation, γHV68-M3.stop grew to lower titers than γHV68 or γHV68-M3.MR in the
brain but spread to and grew normally in the spleen and lung. Expression of several CC chemokines
was significantly induced in the CNS by γHV68 infection. Consistent with M3 acting by blockade of
CC chemokine action, γHV68 induced a neutrophilic meningeal inflammatory infiltrate, while
γHV68-M3.stop induced an infiltrate in which lymphocytes and macrophages predominated. In con-
trast to the important role of M3 in lethal meningitis, M3 was not required for establishment or reac-
tivation from latent infection or induction of chronic arteritis. These data suggest a role for
chemokines in the protection of the nervous system from viral infection and that the M3 protein 
acts in a tissue-specific fashion during acute but not chronic γHV68 infection to limit CC
chemokine–induced inflammatory responses.
J. Clin. Invest. 109:905–914 (2002). DOI:10.1172/JCI200214358.
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γHV68 is a γ2-herpesvirus with homology to Epstein-
Barr virus (EBV), herpesvirus saimiri (HVS), and Kaposi
sarcoma herpesvirus (KSHV, HHV8). γHV68 infects
laboratory mice and can be genetically manipulated
(14, 15), providing a unique tool for identifying host
and viral factors that regulate γ-herpesvirus pathogen-
esis (reviewed in refs. 12, 13). The γHV68 M3 gene
encodes an abundant secreted protein (16) that is capa-
ble of binding to a broad spectrum of chemokines and
blocks chemokine signaling (7, 8). To date, M3 binds
murine CC chemokines with about 100-fold higher
affinities than murine CXC chemokines (8), suggesting
that M3 may selectively block certain classes of
chemokines in vivo. To examine the biologic role of this
chemokine-binding protein in herpesvirus infection,
we constructed a recombinant γHV68-M3.stop mutant
virus that is deficient in production of M3 protein. We
report here that the M3 protein plays a critical role in
acute viral meningitis, but does not have a role in
chronic vasculitis or in the establishment of, or reacti-
vation from, latency.
Methods
Viruses and tissue culture. γHV68 WUMS (ATCC VR1465)
was used for all infections and is designated as wild-type
γHV68. γHV68 was passaged on NIH 3T12 cells for
amplification and was propagated as described previ-
ously (17). NIH 3T12 cells and mouse embryonic fibrob-
lasts (MEFs) were maintained in DMEM, supplemented
with 10% FCS, 100 U/ml penicillin, 100 U/ml strepto-
mycin, and 2 mM L-glutamine (complete DMEM). Cells
were maintained in a 5% CO2 tissue culture incubator at
37°C. MEFs were obtained from either BALB/c or
C57BL/6 mouse embryos as described previously (17).
Generation of virus mutants. The γHV68-M3.stop virus
was generated by Lipofectamine cotransfection of
γHV68 genomic DNA (18) with a gene-targeting plas-
mid. The parental targeting vector, M3-64, contains the
fragment of the γHV68 genome from the SpeI site at
genomic coordinate 4632 to the StuI site at 8242 insert-
ed into the cloning vector Litmus 28. The γHV68-
M3.stop targeting vector was generated by inserting a
linker sequence into the AccI site at 7176. The stop link-
er was formed by annealing the following oligos: 5′-
CTACCTAGGACTAAGT-3′ and 5′-AGACTTAGTCCTAGGT-
3′. This linker inserts three in-frame translational stop
codons, a frameshift mutation, and a novel AvrII site.
Virus was harvested 6 days after transfection, diluted,
plated on NIH 3T12 monolayers, and after an hour of
infection, overlaid with methylcellulose (2% methylcel-
lulose in DMEM supplemented with 5% FCS, antibi-
otics, and L-glutamine) as described previously (15).
One hundred plaques were picked from each transfec-
tion and resuspended in 0.5 ml of complete DMEM.
Five microliters of the resuspended plaque were sub-
jected to proteinase K digestion overnight and then
analyzed by nested PCR specific for the engineered
mutation (outside primers: 5′-AGAGGGGAATGGCA-
ATCTGCCTGTT-3′, 5′-GCATATTTAAGGAGGGTCTCCCT-
GC-3′; inside primers: 5′-CCTTCCTATCCACATCTGT-
GCTCAT-3′, 5′-AAGAGTGG-GTAGACTTAGTCCTAGG-3′).
Positive recombinants were detected with a frequency
of approximately 4% in the first round of plaque purifi-
cation. Plaques containing mutant virus were plaque
purified until homogenous (three rounds).
Small viral stocks were prepared for DNA analysis as
described previously (15). To assess for the presence of
the engineered mutation, Southern analysis was per-
formed with a diagnostic AvrII digest and a 32P-labeled
M3 region probe (bp 5362–7893 of γHV68 WUMS).
Large viral stocks were generated as described previ-
ously (15), and titers were independently determined
by plaque assay three times. Western blot analysis was
performed as described previously (16).
The M3 marker rescue virus was generated by cotrans-
fection of the parental M3-containing plasmid (M3-64)
with viral genome derived from the γHV68-M3.stop viral
stock and plaque purification as above, with the excep-
tion that recombinant plaques were now identified by
assessing for the presence of secreted M3 protein by
ELISA. One hundred microliters of resuspended plaque
were added to NIH 3T12 monolayers in 96-well plates
and incubated at 37°C for 6 days, at which point there
was significant viral cytopathic effect. Supernatants
from these infected monolayers were used to coat an
Immulon II ELISA plate (Thermo Labsystems, Franklin,
Massachusetts, USA) overnight at 4°C. The ELISA was
performed with rabbit antisera raised against bacterial-
ly expressed M3 protein (8) and developed with a horse-
radish peroxidase–conjugated secondary Ab specific to
rabbit immunoglobin. The ELISA was capable of detect-
ing M3 protein in a 1:106 dilution of supernatants infect-
ed with a wild-type resuspended plaque. Recombinant
viruses were detected with a frequency of approximately
4% in the first round of purification. Generation of the
γHV68-M2.stop virus is described elsewhere (19).
Multistep in vitro growth analysis of mutant and wild-type
γHV68 viruses. NIH 3T12 cells were infected with either
γHV68-M3.stop or wild-type γHV68 viruses at a moi of
0.05 in six-well plates to measure multiple cycles of
virus replication. Total infected cell lysates were har-
vested at 12, 24, 48, 72, and 96 hours after infection, as
described previously (15, 20).
Real-time RT-PCR analysis of mutant and wild-type γHV68
viruses. The effect of the M3 mutation on transcription
of the adjacent M2 and M4 genes was determined using
real-time PCR analysis. Transcripts from gene 6, encod-
ing the single-stranded DNA-binding protein, were
quantitated as an internal control for viral RNA recov-
ery. NIH 3T12 cells were infected with either wild-type
γHV68, γHV68-M3.stop, or γHV68-M3.MR at moi = 5,
and total RNA was harvested 18 hours after infection
(TRIzol, Life Technologies Inc., Grand Island, New
York, USA). Two micrograms of total RNA were incu-
bated with 200 ng/µl oligo-dT and 50 ng/µl of random
hexamer at 68°C for 10 minutes, and 20.5 µl of reaction
mix were added containing 1 mM dNTP, 1X First
Strand buffer (Life Technologies Inc.), 20 mM DTT
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(Life Technologies), 2 µl of RNAsin (Promega Corp.,
Madison, Wisconsin, USA), and 100 U Superscript II
(RNAse H–) reverse transcriptase (Life Technologies
Inc.). Reverse transcription was performed at 42°C for
1 hour, 500 µl of water were added, and samples were
boiled for 5 minutes and stored at –20°C. Real-time
PCR (iCycler; Bio-Rad, Hercules, California, USA) was
carried out in 25-µl reactions containing 2.5 µl RT prod-
uct, 1X Gold buffer (Perkin-Elmer Applied Biosystems,
Foster City, , USA), 1:20 volume of dimethyl sulphoxide,
0.2 mM deoxynucleoside triphosphates, 2.5 mM MgCl2,
0.2 U AmpliTaq Gold (Perkin-Elmer Applied Biosys-
tems), 160 nM forward and reverse primers, and
1:30,000 final concentration of SYBR Green (Molecular
Probes Inc., Eugene, Oregon, USA). Dilutions of plas-
mids containing 109–101 copies of genes M2, M4, and
gene 6 were run in parallel for use as a standard curve.
PCR primers used for real-time PCR analysis are as fol-
lows: M2 (sense) 5′-GCCCACCTACAAGACCTTT-3′ and
(antisense) 5′-CCCACTCCACAAAACCTT-3′; M4 (sense) 5′-
GGAGAAGATGATGATATTCCTGT-3′ and (antisense) 5′-
CAGAATAATTTCCTGGATGGA-3′; gene 6 (sense) 5′-
ATGTCTCCCCATATTCTTGC- 3′ and (antisense) 5′-
ACATGGAAGTGTTGGCTGT-3′.
Mice and inoculations. All mice were sex and age
matched and infected between 7 and 9 weeks of age
unless otherwise stated. C57Bl/6J mice were purchased
from The Jackson Laboratory (Bar Harbor, Maine,
USA). CD-1 outbred mice with litters for intracerebral
inoculations were obtained from Charles River Labo-
ratories (Wilmington, Massachusetts, USA). Mice were
bred and maintained at Washington University School
of Medicine in accordance with all federal and univer-
sity policies. Mice infected by the intraperitoneal route
of inoculation were infected with 106 plaque-forming
units (PFU) in 0.5 ml of supplemented DMEM medi-
um unless otherwise noted. For intranasal inoculation,
mice were infected with 4 × 105 PFU in 40 µl of supple-
mented DMEM. For the intracerebral route of inocu-
lation, 21-day-old CD1 or C57B1/6J mice were infect-
ed with varying doses of virus in a 10 µl volume using
a 50-µl Hamilton syringe (Hamilton Co., Reno, Neva-
da, USA) and a 30-gauge Precision-Glide needle (Bec-
ton-Dickinson, Franklin Lakes, New Jersey, USA).
Analysis of infected mice. Plaque assays were performed
as previously described (15, 20). Briefly, mice were sac-
rificed and organs were harvested into sterile, screw-
top 2-ml tubes (Sarstedt Inc., Newton, North Caroli-
na, USA) containing 1 ml of DMEM medium and 100
µl 1-mm zirconia/silica beads (BioSpec Products Inc.,
Bartlesville, Oklahoma, USA) and stored at –80°C
until the plaque assay was performed. Samples were
then thawed on ice and homogenized using the Mini
BeadBeater (BioSpec Products Inc.) for 1 minute at
maximum speed. One hundred microliters of homog-
enized organ were then used for dilutions. The limit of
detection for the plaque assays was 50 PFU. Organs for
pathology were collected into 10% buffered formalin,
fixed for at least 72 hours, and embedded in paraffin
for sectioning and staining with hematoxylin and
eosin or left unstained for immunohistochemistry.
Differential counts were performed in a blinded man-
ner by two investigators.
Immunohistochemistry. Immunohistochemical staining
with immunofluorescence was performed as described
previously (21). Anti-γHV68 polyclonal rabbit serum
and preimmune rabbit serum were diluted 1:1,000 and
added to slides following deparaffinization and anti-
gen retrieval, incubated overnight at 4°C, and washed.
Cy3-conjugated donkey anti-rabbit secondary Ab at a
1:250 dilution was added, incubated at room tempera-
ture for 1 hour, and washed. Slides were counterstained
in a 1:2,000 dilution of Hoechst dye for 15 minutes,
washed, covered with PBS-glycerol (1:1) coverslips, and
stored at 4°C in the dark. No staining was observed in
infected tissues incubated with preimmune serum.
Similarly, no staining was observed in uninfected tis-
sues incubated with immune serum.
RNase protection assay. RNA was harvested from half
brains of individual mice using the RNeasy Midi Kit
from QIAGEN Inc. (Valencia, California, USA). Five
days after intracerebral injection of either DMEM as a
control, 100 PFU of γHV68-M3.MR, or 100 PFU of
γHV68-M3.stop, mice were sacrificed, and half of the
brain was placed in 2 ml of buffer RLT (provided in the
RNeasy kit), and sonicated for 45 seconds. Samples were
then processed according to the manufacturer’s proto-
col. Twenty milligrams of total RNA from each mouse
were then processed using the RiboQuant Multi-Probe
RNase Protection Assay System (PharMingen, San
Diego, California, USA), using the mCK-5 multi-probe
template set according to the manufacturer’s protocol.
Ex vivo limiting dilution reactivation analysis. The fre-
quency of cells capable of reactivating from latency was
determined by a limiting dilution ex vivo reactivation
assay as described previously (15, 17, 20, 22, 23).
Mechanical disrupted cells contained less than 1% live
cells, and thus the presence of preformed virus could be
discerned from virus reactivating from latency as
described previously (15, 17, 20, 22, 23).
Limiting dilution PCR for viral genome-bearing cells. To
detect peritoneal exudate cells and splenocytes harbor-
ing γHV68 genome, a limiting dilution nested PCR
assay was performed as described previously (15, 17, 20,
22, 23). There were no false positives in the data in this
report, and all assays demonstrated approximately one
copy sensitivity per PCR reaction for plasmid DNA.
Statistical analysis. All data were analyzed using Graph-
Pad Prism program (GraphPad Software for Science
Inc., San Diego, California, USA) as described previous-
ly (15, 20). Titer data, virulence data, and differential
counts were compared using a paired t test. The fre-
quencies of reactivation and genome-positive cells were
analyzed by paired t test. Frequencies of reactivation and
genome-positive cells were obtained from cell numbers
at which 63% of wells scored positive for either viral
cytopathic effect or for presence of viral genome based
on Poisson distribution. The data were then subjected
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to nonlinear regression analysis to obtain the single cell
frequency for each limiting dilution analysis.
Results
Targeted disruption of the M3 open reading frame. We dis-
rupted the M3 open reading frame (ORF) by inserting
a translational stop with an accompanying frameshift
mutation into the AccI site at genomic coordinate 7176
(18) (γHV68-M3.stop virus; Figure 1a). This site is 34
amino acids into the 406 amino acids of the ORF, but
is downstream from the end of the secretion signal pep-
tide, such that truncated versions of the protein poten-
tially made by downstream translation initiation
should not be secreted from the cell.
Purification of γHV68-M3.stop provided a homoge-
nous stock, as determined by the presence of the
inserted stop sequence in 50 out of 50 plaques (as
determined by PCR analysis), absence of detectable M3
protein in 50 out of 50 plaques (as determined by
ELISA), and appropriate digestion patterns on South-
ern analysis of 20 out of 20 plaques (data not shown).
Southern analysis of γHV68-M3.stop by restriction
digest with AvrII, using a 32P-labeled M3 region probe
(bp 5362–7893), demonstrated, as predicted, the addi-
tion of an additional AvrII site within the M3 ORF
(Figure 1b). Western analysis of NIH 3T12 cells infect-
ed with the γHV68-M3.stop virus indicated that no
full-length M3 protein, or truncated products (data
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Figure 1
Construction and verification of the γHV68-M3.stop and γHV68-M3.MR viruses. (a) Genomic structure of γHV68, γHV68-M3.stop, and
γHV68-M3.MR in the region of the M3 ORF. (b) Southern blot analysis of γHV68, γHV68-M3.stop, and γHV68-M3.MR. Viral DNA was
purified from viral stocks, digested with AvrII, and analyzed with a probe spanning the M3 ORF (see a). The sizes of the hybridizing bands
are indicated. (c) Western blot analysis of γHV68, γHV68-M3.stop, and γHV68-M3.MR. Total cellular lysate was analyzed with either a
polyclonal Ab to the M3 protein or an mAb to β-actin. (d) Real-time RT-PCR analysis of M2 and M4 genes in NIH 3T12 cells lytically infect-
ed with either wild-type γHV68, γHV68-M3.stop, or γHV68-M3.MR. Gene 6 transcription was analyzed in parallel as a control. Shown are
mean ± SEM of pooled data from at least three independent experiments. NS, no statistically significant difference between transcript lev-
els in cells infected with γHV68-M3.stop compared with cells infected with either γHV68 or γHV68-M3.MR.
Figure 2
Replication of the γHV68-M3.stop virus. (a)
Multistep growth curve. NIH 3T12 mono-
layers were infected with 0.05 PFU per cell of
either γHV68 or γHV68-M3.stop, and sam-
ples were harvested at various times after
infection. The mean and SEM of two 
independent experiments are shown. (b)
C57BL/6 mice were infected with either 
106 PFU intraperitoneally or 4 × 105 PFU
intranasally and harvested at either 4 or 9
days after infection. Lung and spleen were
assayed for viral titer. The mean ± SEM of
two independent experiments (ten mice
total per condition) are shown. i.p.,
intraperitoneal; i.n., intranasal.
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not shown), could be detected with a polyclonal Ab to
the M3 protein (Figure 1c).
The M3 stop mutation lies 1,233 bp from the pre-
dicted translational start of the adjacent M4 gene and
2,548 bp from the known transcriptional start site of
the adjacent M2 gene, making it unlikely that insertion
of the M3 mutation would alter transcription of either
M2 or M4 (24, 25). To determine if the M3.stop muta-
tion altered M2 or M4 transcription, we performed real-
time RT-PCR analysis of transcript levels in NIH 3T12
fibroblasts infected with wild-type γHV688, γHV68-
M3.stop, or γHV68-M3.MR. Transcript levels from the
M2 and M4 genes were not significantly altered by the
presence of the M3.stop mutation (Figure 1d).
To rule out the presence of distal mutations in γHV68-
M3.stop that might result in phenotypic alterations in
γHV68-M3.stop, we constructed and purified a marker
rescue virus (γHV68-M3.MR), which reconstituted wild-
type M3 ORF sequence into γHV68-M3.stop. Southern
analysis of γHV68-M3.MR after AvrII digestion demon-
strated, as expected, the loss of the engineered AvrII site
(Figure 1b), and Western analysis indicated expression
of the M3 protein (Figure 1c).
M3 is not required for efficient replication in cultured cells,
spleen, or lung. Based on our ability to isolate the γHV68-
M3.stop mutant, the M3 ORF is nonessential for in
vitro replication. To evaluate whether M3 has a role in
in vitro replication, we compared γHV68-M3.stop and
wild-type γHV68 during multiple rounds of replication
in NIH 3T12 cells (Figure 2a). We found that M3 is not
required for efficient replication in immortalized
murine fibroblasts. Similarly, M3 was not required for
efficient replication of γHV68 in either the spleen or
lung of C57BL/6 (B6) mice 4 or 9 days after either
intraperitoneal or intranasal inoculation (Figure 2b).
M3 is essential for efficient induction of meningitis and viru-
lence after intracerebral inoculation. Chemokine expression
has been demonstrated to increase after CNS infection
with numerous viruses (26–29), and chemokines have
been postulated to play an important role in CNS viral
pathogenesis (reviewed in ref. 30). Considering that
γHV68 is capable of infecting numerous cell types with-
in the brain (31), we tested the hypothesis that the M3
protein has a role after intracerebral infection of 21-
day-old immunocompetent CD1 mice. γHV68-M3.stop
was 100-fold less virulent than wild-type γHV68 after
intracerebral inoculation (Figure 3a). This attenuation
was specific to the mutation in the M3 ORF, since
γHV68-M3.MR virus was equal in virulence to γHV68.
A decrease in virulence of the γHV68-M3.stop com-
pared with γHV68-M3.MR after intracerebral inocula-
tion was also demonstrated in B6 mice, assuring that
the attenuated phenotype observed in CD1 mice is not
strain dependent (P = 0.0263, sixty 21-day-old BL6 mice
challenged with 1, 10, and 100 PFU of γHV68-M3.stop
or γHV68-M3.MR).
We considered that M3 might be required for effi-
cient replication in the brain despite the lack of a
requirement for M3 in replication in the spleen and
lung (above). We therefore determined the viral titer
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Figure 3
Virulence of γHV68-M3.stop virus. (a) CD1 mice (21 days old) were
inoculated intracerebrally with various doses of γHV68, γHV68-
M3.stop, or γHV68-M3.MR, and followed for 2 weeks. Each data
point represents the mean ± SEM of three independent experiments
(30 mice total per dose, *P < 0.0001). (b) γIFNR–/– mice (n = num-
ber of mice across five separate experiments) were infected with 106
PFU of either γHV68 or γHV68-M3.stop and followed for 84 days.
Figure 4
Viral titer after intracerebral infection with γHV68-M3.stop virus. CD1
mice (21 days old) were inoculated intracerebrally with 100 PFU of
either γHV68, γHV68-M3.stop, or γHV68-M3.MR. At various points
after infection, viral titer in the brain (a), spleen (b), or lung (c) was
determined. Each data point represents the mean ± SEM of two inde-
pendent experiments (ten mice total per condition). *P = 0.0019.
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within the brain, lung, and spleen at various days after
intracerebral inoculation with 100 PFU of either
γHV68-M3.stop, γHV68, or γHV68-M3.MR. At the peak
of viral replication in the brain (day 5; Figure 4a), there
was approximately a tenfold decrease in viral titer in the
brain that was specific to the mutation in the M3 ORF
(P = 0.0019). This decrease was considerably smaller at
day 7 after inoculation. Consistent with data after
intraperitoneal or intranasal inoculation (Figure 2),
after intracerebral inoculation there was no role for M3
in viral replication in lung or spleen (Figure 4, b and c).
To assess the location and extent of viral replication
within the brain, as well as the nature of the inflamma-
tory response to the infection, we performed histologi-
cal examination of the brains of infected mice. Exami-
nation of sections at days 5 and 7 after infection
indicated discontinuous areas of meningeal inflamma-
tion in mice infected with either γHV68 or γHV68-
M3.stop. Meningeal inflammation was most prominent
in the region of the cerebellum and basal forebrain.
Examination of these slides with Ab specific to γHV68
antigen indicated that virus was present at the sites of
inflammation in similar patterns for both γHV68 (Fig-
ure 5, a–c) and γHV68-M3.stop (Figure 5, d–f).
Strikingly, the nature of the inflammatory infiltrate
was different after infection with γHV68 compared with
γHV68-M3.stop. γHV68 and γHV68-M3.MR infection
was associated with a marked preponderance of neu-
trophils in the meninges (Figure 6, a, c, d, and f). In con-
trast, the proportion of lymphocytes and macrophages
was increased in the meninges of mice infected with
γHV68-M3.stop (Figure 6, b and e). Differential counts
conducted in a blinded manner confirmed that lack of
M3 was associated with a considerable change in the
inflammatory infiltrate (Figure 6g). Mutation of M3 led
to a statistically significant increase in lymphocytes and
macrophages (P = 0.0449 and P = 0.0004, respectively)
and a decrease in neutrophils (P < 0.0001) relative to
infection with γHV68-M3.MR.
Chemokine expression is induced during γHV68-induced
meningitis. Since M3 has an important role in neu-
rovirulence and is a high-affinity CBP, we wished to
determine whether M3 ligands are expressed during
CNS infection with γHV68. We therefore performed a
RNase protection assay to determine whether
chemokine expression increases in response to infec-
tion with γHV68. As shown in Figure 7, there was 
no detectable expression of any of the chemokines
assayed in either naive mice or in mice 5 days after
mock infection. In contrast, expression of CC
chemokines RANTES, MIP-1β, and MCP-1, as well as
the CXC chemokine IP-10, were detected 5 days after
infection with either γHV68-M3.MR or γHV68-
M3.stop (Figure 7). These data support the hypothesis
that M3 may regulate CNS disease via its capacity to
sequester inflammatory chemokines.
M3 does not play a role in regulating chronic inflammation
in immunocompromised mice. Since M3 is important for
regulating inflammatory responses during acute
γHV68 infection, we considered the possibility that the
M3 protein may regulate chronic inflammatory
responses to γHV68 infection. We therefore examined
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Figure 5
Meningeal localization of viral antigen after infection with γHV68 and γHV68-M3.stop. Immunohistochemical localization of viral antigen
after intracerebral inoculation of 21-day-old CD1 mice with 100 PFU of either γHV68 (a–c) or γHV68-M3.stop (d–f) demonstrates that viral
antigen is present in the meninges of mice infected with either virus. (a and d) Hematoxylin and eosin–stained sections of brain. (b and e) Sec-
tions at same magnification, stained with a polyclonal Ab to γHV68 and a Cy-3–conjugated secondary Ab (red). Slides were counterstained
with Heochst dye, staining nuclei blue. (c and f) Higher magnification of boxed areas in b and e. Immunohistochemistry with preimmune
serum as the primary Ab showed no reactivity with adjacent sections. Sections shown are representative examples of six mice, infected on two
separate occasions. The scale bars represent 250 µm for a, b, d, and e , and 50 µm for c and f.
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the role of M3 in inflammatory aortitis and splenic
atrophy induced by γHV68 in IFNγR–/– mice infected
for weeks to months with either γHV68-M3.stop or
γHV68 (21, 32). After infection with 2 × 106 PFU of
either γHV68-M3.stop or γHV68, INFγR–/– mice died
with similar kinetics and frequency (Figure 3b). Histo-
logical examination of aortic inflammation and splenic
atrophy in these mice indicated that M3 plays no role
in either the penetrance or severity of splenic or aortic
lesions caused by either virus (data not shown).
M3 is not required for establishment or reactivation from
latency. Since the region of the M3 ORF is transcribed
in latently infected tissues (33–35) and a recent study
indicated a γHV68 mutant virus in which a LacZ cas-
sette was placed in the M3 gene has a marked reduc-
tion in establishment of latency (36), we examined
whether γHV68-M3.stop was capable of establishing
a latent infection in B6 mice after either intranasal or
intraperitoneal inoculation. At either 2 weeks (Figure
8, a–d) or 7 weeks after infection (data not shown),
splenocytes and peritoneal exudate cells were assessed
for their ability to reactivate from latency in an ex vivo
limiting dilution analysis (22, 23). We found that sim-
ilar frequencies of reactivating cells were recovered
after infection with either γHV68-M3.stop or γHV68,
regardless of route of inoculation. To measure per-
sistent replication in samples, replicate cell aliquots
were mechanically disrupted. This procedure kills
more than 99% of cells, but has at most a twofold
effect on viral titer (22), thus allowing experimental
distinction between reactivation from latency (which
requires live cells) and persistent replication of virus
in tissues. No significant persistent replication of
either virus was detected under any of the experimen-
tal conditions (Figure 8, a–d).
Using a nested PCR to detect γHV68 genome-bearing
(15) cells, we found that at 2 weeks after infection, sim-
ilar frequencies of cells harbored γHV68 genome in both
splenocytes and peritoneal exudate cells after infection
with either γHV68-M3.stop or γHV68 (Figure 8, e–h),
demonstrating that the M3 protein is not required for
establishment of or reactivation from latency.
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Figure 6
The M3 protein alters the inflammatory response to γHV68. Hematoxylin and eosin–stained sagital brain sections from the basal forebrain
of CD1 mice infected with γHV68 (a and d), γHV68-M3.stop (b and e), or γHV68-M3.MR (c and f) 5 days previously. The boxed areas in
a–c are shown at higher magnification in d–f. The arrows in d and f indicate neutrophils (PMN). The arrow in e indicates a lymphocyte (L).
(g) Differential counts of meningeal infiltrates of mice infected 5 days previously with the indicated viruses. Shown are mean ± SEM of
pooled numbers from two independent investigators performing differential counts in a blinded manner on sections from four mice infect-
ed with γHV68, eight mice infected with γHV68-M3.MR, and eight mice infected with γHV68-M3.stop (*P = 0.0449, **P = 0.0004, and
***P < 0.0001). Scale bars, 100 µm. Mono/Blast, monocytes or lymphoblasts.
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Discussion
The coordination of leukocyte recruitment into sites of
infection is a critical aspect of the inflammatory response.
Chemokines play a central role in this process through
the activation and mobilization of macrophages, lym-
phocytes, dendritic cells, natural killer cells, and granu-
locytes (37). Recently, a number of reports have docu-
mented the possible involvement of chemokines in the
immunopathogenesis of different infectious diseases of
the CNS (26–29). Our data is most consistent with a role
for CC chemokines in protecting the CNS from viral
infection. Moreover, secretion of a selective high-affinity
CBP by a herpesvirus suggests that soluble chemokines
play a central role in herpesvirus infection. We have exam-
ined, through the use of a viral mutant lacking the M3
protein, the role of chemokines in acute, chronic, and
latent infection with the γ2-herpesvirus γHV68.
Absence of the M3 protein from
γHV68 infection resulted in a signifi-
cantly attenuated phenotype, but
notably only under specific circum-
stances. There was no apparent defect
in the ability of the virus to replicate or
spread from the site of infection to dis-
tal organs after either intraperitoneal
or intranasal inoculation, indicating
that either chemokines do not con-
tribute to viral clearance under these
conditions or that the virus contains
other proteins that can compensate for
the lack of the M3 protein. In contrast
to this result, the M3-deficient virus
demonstrated decreased virulence after
intracerebral inoculation, with a con-
comitant decrease in viral titer. These
data, combined with the fact that both
wild-type and M3-deficient viruses
replicated to similar levels in distal
organs after intracerebral inoculation,
suggest that chemokines may have a
greater role in protection of the CNS
from herpesvirus infection than other
organ systems within the host.
The predominately neutrophilic infil-
trate associated with infection in the
presence of the M3 protein, compared
with the relative abundance of lympho-
cytes and macrophages after infection
with a virus lacking the M3 protein,
shows that the M3 protein significantly
alters the inflammatory response to
γHV68. Whether these alterations in
inflammation are dependent on, or
independent of, the effects of M3 on
viral replication is not known. However,
examination of the chemokines typical-
ly produced during CNS infection sug-
gests a mechanism by which M3 could
alter the inflammatory response and
thereby contribute to virulence. In experimental and
clinical bacterial meningoencephalitis there is domi-
nant cerebral production of the neutrophil and 
monocyte attractant chemokines IL-8, MIP-2, GROα, 
MCP-1, MIP-1α, and MIP-1β, and the inflammatory
infiltrates consist of predominantly neutrophils and
monocytes (38–40). In contrast, during viral menin-
goencephalitis, including γHV68 (Figure 5 and 6), cere-
bral expression of the lymphocyte and monocyte
chemoattractants IP-10, MCP-1, and RANTES pre-
dominates (29). This pattern of chemokine expression
would be predicted to induce an infiltrate consisting
primarily of lymphocytes and monocytes (30). The M3
protein is capable of binding to MIP-1α, MCP-1, and
RANTES, while it does not bind with appreciable affin-
ity to IL-8, MIP-2, GROα, or IP-10 (8). Thus, by binding
to and antagonizing the activity of chemokines such as
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Figure 7
Enhanced chemokine mRNA expression after intracerebral inoculation with γHV68.
RNA was harvested from brains of naive mice, mock-infected mice, or mice infected with
100 PFU of either γHV68-M3.MR or γHV68-M3.stop and subjected to RNase protec-
tion analysis. Twenty micrograms of total RNA were added per sample, except for the
positive control mouse splenocyte RNA lane, which contained 2 µg RNA. Differences
in loading between lanes were at most tenfold (e.g., compare L32 in Mock, lane 2, with
γHV68-M3.MR, lane 1), while differences in expression of chemokines were in the range
of 600-fold (e.g., compare RANTES in Mock, lane 2, with γHV68-M3.MR, lane 1). Band
intensity was quantified using the STORM Phosphoimager software package (Molecu-
lar Dynamics, Piscataway, New Jersey, USA).
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MIP-1α, MCP-1, and RANTES, the M3 protein could
shift the inflammatory response from lymphocytes and
monocytes to neutrophils, which may be less effective at
controlling viral infection.
Data from these studies demonstrate no role for the
M3 protein in two aspects of chronic infection-induc-
tion of aortic inflammation in IFN-γ–unresponsive
mice and in the establishment, maintenance of, or reac-
tivation from latency. Consistent with the idea that the
M3 protein has a role only in limited aspects of γHV68
infection, two measures of chronic disease — vasculitis
and splenic atrophy in IFN-γ–unresponsive mice —
were unchanged after infection with a virus deficient in
production of the M3 protein (data not shown). It is
intriguing that the data presented here demonstrate no
role for the M3 protein in either establishment, main-
tenance, or reactivation from latency, despite a recent
study indicating that a virus containing a LacZ inser-
tion disrupting the M3 ORF (γHV68-M3LacZ) has a
dramatic reduction in establishment of latency (36). It
is possible that the phenotype of γHV68-M3LacZ
reported by Bridgeman et al. (36) is due to the insertion
of a large transcriptionally active cassette in the M3
region rather than deletion of M3. This is consistent
with findings showing that insertion of a LacZ cassette
into the γHV68 M1 locus generated viral phenotypes
not attributable to deletion of M1 (15). It is possible
that the presence of the LacZ cassette in the M3 locus
alters the expression of other γHV68 genes, and it is
these other gene products that are responsible for the
altered phenotype. For example, the phenotype of a
stop mutant in the M2 gene (19), which is adjacent to
the M3 gene, is very similar to the phenotype reported
by Bridgeman et al. for γHV68-M3LacZ, raising the pos-
sibility that the phenotype attributed to M3 by Bridge-
man et al. is due to alterations in M2. Insertion of the
M3.stop mutation did not alter transcript levels from
either M2 or M4 (Figure 1d).
The lack of a role for M3 in latency is somewhat sur-
prising since several studies have indicated that the
region of the M3 ORF is transcriptionally active during
latency (33–35). There are several possible interpreta-
tions of these data. First, we have found previously that
the timing of transcription is not predictive of the func-
tion of a gene in vivo. For example, the v-cyclin is an
abundantly transcribed lytic cycle gene, but its primary
role in vivo is in the regulation of reactivation from
latency (20, 41). Second, transcriptional assays may be
indicating that the locus surrounding the M3 ORF is
active during latency, with a gene product other than
the M3 protein critical for establishment of latency.
Third, it is possible that the M3 protein has a role in
latency that has not been demonstrated by the assays
described here. Finally, it is possible that the latent
populations examined for transcriptional activity con-
tain a few cells that are replicating virus. The relative
abundance of the M3 transcript (16) might lead to it
scoring positive in a transcriptional assay while other
lytic transcripts remain below the limit of detection. It
is important to note that despite the lack of a role for
M3 in latency and reactivation, it is possible that the
M3 protein does have a role in chronic infection that is
as yet undetected.
This work shows that the M3 protein has a potent
capacity to regulate inflammation in vivo, resulting in
increased virulence during acute infection. The capacity
to inhibit lymphocyte-dependent inflammation raises
the possibility that M3 may alter inflammatory process-
es that are induced by CC chemokines without compro-
mising all chemokine-based host responses. Since M3
can inhibit CC chemokine-dependent responses, M3
may be useful clinically to combat diseases in which lym-
phocytes and macrophages cause tissue destruction. M3
may also provide a tool for analyzing the role of
chemokines in other experimental models of disease.
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Figure 8
γHV68-M3.stop establishes and reactivates from latency normally.
Sixteen days after inoculation with either 106 PFU intraperitoneally
(a, b, e, and f) or 4 × 105 PFU intranasally (c, d, g, and h), spleno-
cytes (a, c, e, and g) and peritoneal exudate cells (b, d, f, and h) were
harvested from B6 mice. Ex vivo reactivation (a, b, c, and d) was
monitored by plating cells over an indicator monolayer and moni-
toring for viral cytopathic effect 21 days after plating (square sym-
bols). Duplicate cell samples were mechanically disrupted to control
for persistent viral replication (triangle symbols, denoted as disrupt-
ed in the figure). (e, f, g, and h) Percentage of cells harboring viral
genome was assessed through a limiting dilution nested PCR assay.
Data are pooled from three independent experiments of five mice per
infectious condition (15 mice total per condition).
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